// App-Quantinova.ai

7027 : Patient-reported outcomes (PRO) from a global phase 3 randomized controlled trial (RCT) of inotuzumab ozogamicin (InO) vs standard care (SC) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

Researchers

Presenter

  • Hagop M Kantarjian

Principal Investigators

  • Yun Su

  • Helen Bhattacharyya

  • Eric Yan

  • Mark Shapiro

  • Joseph C Cappelleri

Medical Centers

  • The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX

  • Pfizer Inc, New York, NY

  • Pfizer Oncology, La Jolla, CA

  • Pfizer Inc., Cambridge, MA

  • Pfizer, Groton, CT

Locations

  • United States

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

  • Mitoxantrone

  • fludarabine tablet

  • Cytarabine liposomal

  • ara-c

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • III

Study Id's

  • NCT01564784

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved